NFRP Outreach and Invitation for Response

Per-recipient award not stated for business, individual, nonprofit, other legal entity, public agency, tribal government, unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled additional information on eligibility, closing Not stated.

In one sentence

NFRP Outreach and Invitation for Response does not state a per-recipient award amount, open to business, individual, nonprofit, other legal entity, public agency, tribal government, unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled…

Record fields
Program pool (total)
Not confirmed
Total across all awards in this programme. Not an amount any single applicant can receive.
Award ceiling (per project)
Not confirmed
The document is an outreach and invitation for response, not a formal solicitation, so no funding amounts are specified.
Award floor
Not confirmed
Typical award
Not confirmed
Deadline
Not stated
Deadline type
unknown
Opens
Not stated
Status
Forecasted
Eligible entities
Business · Individual · Nonprofit · Other Legal Entity · Public Agency · Tribal Government · Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility
Geography
Not stated
Matching funds
Yes
Disbursement
Not confirmed
Application effort
Not confirmed
Currency
USD

How much money is available?

Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.

Program pool (total)Across all awards this cycle
Not stated
Award ceiling (per project)The most one applicant can receive
Not stated

Source wording: “The document is an outreach and invitation for response, not a formal solicitation, so no funding amounts are specified.

Who can apply?

use

Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis

Source field: use of funds
size limit

Not stated

Source field: applicant size limit
clause text

Applicants must have demonstrated history of collaborative research and demonstrated access to patient populations for Phase I and II clinical trials. Industry partners may be required.

We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.

When does it close?

Not statedunknown deadline

This is an outreach document requesting feedback, not a formal solicitation with a deadline.

What can the money be used for?

Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis

These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.

How hard is the application?

Application effort
Not confirmed
Disbursement
Not confirmed
Matching funds
Yes
Research OTAs require cost sharing, with Government funds not to exceed the total amount provided by other parties to the maximum extent practicable. Government funds shall not be front-loaded, with certain matches being required before additional Government funds are made available.

Who has received this funding?

No award records yet

We hold no prior awards for this programme. That is a gap in what we have connected, not a finding that the programme has never funded anyone — check the official page, which may list past recipients.

Common questions

Every answer below is a stored field from this record. Questions the source did not answer are not asked.

Who is eligible to apply?
Business, Individual, Nonprofit, Other Legal Entity, Public Agency, Tribal Government, Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
What can the funding be used for?
Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis, as classified by the source.
Is matching funding required?
Yes. This programme requires matching funds. Research OTAs require cost sharing, with Government funds not to exceed the total amount provided by other parties to the maximum extent practicable. Government funds shall not be front-loaded, with certain matches being required before additional Government funds are made available.
Provenance
Source pagegrants.gov
Retrieved2026-08-31
MethodAutomated check
First seen2026-08-31

The official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.